Spelling suggestions: "subject:"acute heart failure"" "subject:"scute heart failure""
11 |
The role of B-type natriuretic peptide in diagnosing acute decompensated heart failure in chronic kidney disease patientsKadri, Amer N., Kaw, Roop, Al-Khadra, Yasser, Abumasha, Hasan, Ravakhah, Keyvan, Hernandez, Adrian V., Tang, Wai Hong Wilson January 2018 (has links)
Introduction: Chronic kidney disease (CKD) and congestive heart failure (CHF) patients have higher serum B-type natriuretic peptide (BNP), which alters the test interpretation. We aim to define BNP cutoff levels to diagnose acute decompensated heart failure (ADHF) in CKD according to CHF subtype: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Material and methods: We reviewed 1,437 charts of consecutive patients who were admitted for dyspnea. We excluded patients with normal kidney function, without measured BNP, echocardiography, or history of CHF. BNP cutoff values to diagnose ADHF for CKD stages according to CHF subtype were obtained for the highest pair of sensitivity (Sn) and specificity (Sp). We calculated positive and negative likelihood ratios (LR+ and LR–, respectively), and diagnostic odds ratios (DOR), as well as the area under the receiver operating characteristic curves (AUC) for BNP. Results: We evaluated a cohort of 348 consecutive patients: 152 had ADHF, and 196 had stable CHF. In those with HFpEF with CKD stages 3–4, BNP < 155 pg/ml rules out ADHF (Sn90%, LR– = 0.26 and DOR = 5.75), and BNP > 670 pg/ml rules in ADHF (Sp90%, LR+ = 4 and DOR = 6), with an AUC = 0.79 (95% CI: 0.71–0.87). In contrast, in those with HFrEF with CKD stages 3–4, BNP < 412.5 pg/ml rules out ADHF (Sn90%, LR– = 0.19 and DOR = 9.37), and BNP > 1166.5 pg/ml rules in ADHF (Sp87%, LR+ = 3.9 and DOR = 6.97) with an AUC = 0.78 (95% CI: 0.69–0.86). All LRs and DOR were statistically significant. Conclusions: BNP cutoff values for the diagnosis of ADHF in HFrEF were higher than those in HFpEF across CKD stages 3–4, with moderate discriminatory diagnostic ability. / Revisión por pares
|
12 |
Empagliflozins effekter vid behandling av akut hjärtsviktSathornkit, Suchada January 2023 (has links)
Akut hjärtsvikt definieras som en debut eller försämring av hjärtsvikt. Hjärtsvikt är ett allvarligt tillstånd där hjärtat inte upprätthåller adekvat hjärtminutvolym för att möta kroppens metaboliska behov vilket leder till trötthet och försämrad livskvalitet. Symtom som relaterar till systemisk vätskeansamling är vanliga vid akut hjärtsvikt. Vätskeansamling och hypoperfusion ökar morbiditet och mortalitet. Patienter med akut hjärtsvikt behöver således snabba och effektiva behandlingar, men också långtidsbehandling efter utskrivning. Avsvällande/vattendrivande behandling är hörnstenen i den terapeutiska behandlingen och loopdiuretika anses som det mest effektiva och snabbverkande läkemedlet. I dagsläget är empagliflozin ett rekommenderat läkemedel för behandling av kronisk hjärtsvikt med nedsatt ejektionsfraktion, då empagliflozins diuretiska egenskap kan stärka effekten av loopdiuretika. Syftet med detta examensarbete var att beskriva effekter hos empagliflozin vid behandling av akut hjärtsvikt som en litteraturstudie. En sökning av randomiserade kliniska prövningar gjordes i PubMed där nio artiklar valdes ut för att ingå i detta examenarbete. Resultatet av de granskade artiklarna visade att empagliflozin som tilläggsbehandling till loopdiuretika ökade urinutsöndring hos patienterna. Resultatet visade också en statistiskt signifikant minskning av NT-proBNP i studierna vars behandlingstid var 5, 7, 15 och 30 dagar jämfört med placebo. Vidare minskade empagliflozin också plasmavolymen och mängden urinsyran i plasman. Två av studierna rapporterade en statistiskt signifikant ökning i andel röda blodkroppar i behandlingsgruppen. Insättning av empagliflozin, hos kliniskt stabila sjukhusvårdade patienterna i studien EMPULSE, gav en statistiskt signifikant klinisk nytta definierat som ett hierarkiskt kompositmått av död oavsett orsak, antal hjärtsviktsepisoder, tid till första hjärtsviktsepisod och klinisk meningsfull förbättring i KCCQ-TSS med vinstratio 1,36. Vidare gav empagliflozin en positiv effekt på viktminskning, ökad diuretisk respons, ödemlindring och ökad livskvalitet under 90 dagars behandling. Hos patienter som fick empagliflozin sänktes eGFR något till en början men återställdes senare. Det fanns dock inte någon statistiskt signifikant skillnad i eGFR mellan grupperna. En av studierna visade på en signifikant minskning av biomarkörer hos patienter som fick empagliflozin vilket gav en njurfunktionsskyddande effekt mot akut njurskada. Slutsatsen var att empagliflozin gav gynnsamma effekter såsom till exempel avsvällande/vätskedrivande effekt och klinisk fördel hos patienter med såväl akut de novo som med dekompenserad kronisk hjärtsvikt vilket betydde att läkemedlet var både säkert och effektivt. I framtiden behöver effekterna dock styrkas genom ytterligare studier med större antal deltagare och under längre behandlingstid efter sjukhusutskrivning.
|
13 |
Rationale and Design of JenaMACS—Acute Hemodynamic Impact of Ventricular Unloading Using the Impella CP Assist Device in Patients with Cardiogenic ShockHaertel, Franz, Lenk, Karsten, Fritzenwanger, Michael, Pfeifer, Ruediger, Franz, Marcus, Memisevic, Nedim, Otto, Sylvia, Lauer, Bernward, Weingärtner, Oliver, Kretzschmar, Daniel, Dannberg, Gudrun, Westphal, Julian, Baez, Laura, Bogoviku, Jurgen, Schulze, P. Christian, Moebius-Winkler, Sven 05 December 2023 (has links)
Introduction: Cardiogenic shock due to myocardial infarction or heart failure entails a
reduction in end organ perfusion. Patients who cannot be stabilized with inotropes and who experience increasing circulatory failure are in need of an extracorporeal mechanical support system.
Today, small, percutaneously implantable cardiac assist devices are available and might be a solution
to reduce mortality and complications. A temporary, ventricular, continuous flow propeller pump
using magnetic levitation (Impella®) has been approved for that purpose. Methods and Study Design: JenaMACS (Jena Mechanical Assist Circulatory Support) is a monocenter, proof-of-concept
study to determine whether treatment with an Impella CP® leads to improvement of hemodynamic
parameters in patients with cardiogenic shock requiring extracorporeal, hemodynamic support. The
primary outcomes of JenaMACS are changes in hemodynamic parameters measured by pulmonary
artery catheterization and changes in echocardiographic parameters of left and right heart function
before and after Impella® implantation at different support levels after 24 h of support. Secondary
outcome measures are hemodynamic and echocardiographic changes over time as well as clinical
endpoints such as mortality or time to hemodynamic stabilization. Further, laboratory and clinical safety endpoints including severe bleeding, stroke, neurological outcome, peripheral ischemic
complications and occurrence of sepsis will be assessed. JenaMACS addresses essential questions of
extracorporeal, mechanical, cardiac support with an Impella CP® device in patients with cardiogenic
shock. Knowledge of the acute and subacute hemodynamic and echocardiographic effects may help
to optimize therapy and improve the outcome in those patients. Conclusion: The JenaMACS study
will address essential questions of extracorporeal, mechanical, cardiac support with an Impella CP®
assist device in patients with cardiogenic shock. Knowledge of the acute and subacute hemodynamic
and echocardiographic effects may help to optimize therapy and may improve outcome in those
patients. Ethics and Dissemination: The protocol was approved by the institutional review board and
ethics committee of the University Hospital of Jena. Written informed consent will be obtained from
all participants of the study. The results of this study will be published in a renowned international
medical journal, irrespective of the outcomes of the study. Strengths and Limitations: JenaMACS is
an innovative approach to characterize the effect of additional left ventricular mechanical unloading
during cardiogenic shock via a minimally invasive cardiac assist system (Impella CP®) 24 h after
onset and will provide valuable data for acute interventional strategies or future prospective trials.
However, JenaMACS, due to its proof-of-concept design, is limited by its single center protocol, with
a small sample size and without a comparison group.
|
14 |
Comparación de la magnitud de asociación entre Ancho de distribución eritrocitaria elevado y mortalidad a un año en pacientes con insuficiencia cardíaca aguda atendidos en el servicio de cardiología de un hospital terciario: Análisis del rol del estatus anémico / Comparison of the Magnitude of Association Between Elevated Red Cell Distribution Width and One-Year Mortality in Patients with Acute Heart Failure Attended in the Cardiology Service of a Tertiary Hospital: Analysis of the Role of Anemic StatusMaita Arauco, Sherelym Alessandra Harumi, Quispe Vasquez, Sthepanie María 28 October 2021 (has links)
Introducción: El ancho de distribución eritrocitaria elevado, ha demostrado ser mejor para el pronóstico de mortalidad, que otros marcadores convencionales. El objetivo del presente estudio es conocer si el estatus anémico modifica la magnitud de asociación de RDW elevado y mortalidad a un año en pacientes con IC aguda.
Metodología: Estudio observacional de cohorte retrospectivo. Se utilizó una base secundaria. Se incluyeron participantes > 18 años hospitalizados con el diagnóstico de insuficiencia cardiaca aguda. Se estableció la razón de riesgos como medida de asociación y para medir la fuerza de asociación entre las variables principales aplicamos un modelo lineal generalizado crudo y ajustado de la familia Poisson.
Resultados: Se incluyeron 709 participantes con edad promedio de 73.48 años. Se encontró que el riesgo de morir a 1 año es 3 veces más con RDW elevado (RR= 3.05, IC 95%: 1.39-6.66). También se evidencia mayor riesgo de morir con proBNP (RR= 1.09, IC 95%: 1.07-1.11). En los participantes anémicos el riesgo de morir al año es 2 veces más con RDW elevado (RR=2.18, IC 95%: 0.91-5.22) y en los no anémicos la variable RDW elevado mantuvo significancia estadística con mortalidad a 1 año (RR=6.95, IC 95%: 1.65-29.23).
Conclusión: RDW elevado se asocia a mortalidad a 1 año en pacientes con ICA tanto anémicos como no anémicos. Se encontró un aumento de la magnitud de asociación en pacientes no anémicos. / Aim. The high distribution width of erythrocytes has been shown to be better for the prognosis of mortality than other conventional markers. The objective of the present study is to know if the anemic state modifies the magnitude of the association of elevated RDW and mortality at one year in patients with acute HF.
Methodology: Retrospective observational cohort study. A secondary base was used. Participants> 18 years of age hospitalized with a diagnosis of acute heart failure were included. The risk ratio was established as a measure of association and to measure the strength of association between the main variables, a crude and adjusted generalized linear model of the Poisson family was applied.
Results: 709 participants were included with a mean age of 73.48 years. The risk of dying after 1 year was found to be 3 times higher with high RDW (RR = 3.05, 95% CI 1.39-6.66). There is also an increased risk of dying with proBNP (RR = 1.09, 95% CI 1.07-1.11). In anemic participants, the risk of dying at 1 year is 2 times higher with high RDW (RR = 2.18, 95% CI: 0.91-5.22) and in non-anemic participants, the high RDW variable maintained statistical significance with 1-year mortality (RR = 6.95, 95% CI: 1.65-29.23).
Conclusion: Elevated RDW is associated with one-year mortality in patients with AHF, both anemic and non-anemic. An increase in the magnitude of the association was found in non-anemic patients. / Tesis
|
Page generated in 0.0744 seconds